Cristian Massacesi
Medical Oncology
Oncology and Radiotherapy Department of Ancona
Ancona
Italy
Name/email consistency: high
- Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Massacesi, C., Terrazzino, S., Marcucci, F., Rocchi, M.B., Lippe, P., Bisonni, R., Lombardo, M., Pilone, A., Mattioli, R., Leon, A. Cancer (2006)
- Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. Massacesi, C., La Cesa, A., Marcucci, F., Pilone, A., Rocchi, M.B., Zepponi, L., Santini, D., Tonini, G., Burattini, L. Oncology (2006)
- Short communication: the efficacy of fixed dose rate infusion of gemcitabine combined with IFN-alpha2a in patients with advanced refractory renal cell carcinoma. Massacesi, C., Burattini, L., Marcucci, F., Bonsignori, M. J. Interferon Cytokine Res. (2005)
- Low dose-intensity docetaxel in the treatment of pre-treated elderly patients with metastatic breast cancer. Massacesi, C., Marcucci, F., Boccetti, T., Battelli, N., Pilone, A., Rocchi, M.B., Bonsignori, M. J. Exp. Clin. Cancer Res. (2005)
- Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factors. Massacesi, C., Santini, D., Rocchi, M.B., La Cesa, A., Marcucci, F., Vincenzi, B., Delprete, S., Tonini, G., Bonsignori, M. Anticancer. Drugs (2003)
- Serum tumor markers may precede instrumental response to chemotherapy in patients with metastatic cancer. Massacesi, C., Rocchi, M.B., Marcucci, F., Pilone, A., Galeazzi, M., Bonsignori, M. Int. J. Biol. Markers (2003)